Evidence map›Paper›PMID 28270924›Full record

ArticleCanadian journal of kidney health and disease2016

A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy.

Srinivasan Beddhu, Rebecca Filipowicz, Bin Wang, Guo Wei, Xiaorui Chen, Abinash C Roy, Scott L DuVall, Hanadi Farrukh, Arsalan N Habib, Terrence Bjordahl and 6 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of kidney health and disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01350388 (Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease), which is not on this map. Cited by 27 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 6 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01350388 nacompletednot on this map

Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease

TypeinterventionalSponsorUniversity of UtahRan2011 to 2013Enrolled80ConditionsChronic Kidney Disease, DiabetesArmsFebuxostat, Placebo
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 6 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Xanthine Oxidoreductase Inhibitors.Handbook of experimental pharmacology · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Srinivasan BeddhuDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA; Department of Veterans Affairs, Salt Lake City Health Care System, UT, USA.
Rebecca FilipowiczDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA.
Bin WangDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA.
Guo WeiDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA.
Xiaorui ChenDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA.
Abinash C RoyDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA.
Scott L DuVallDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA; Department of Veterans Affairs, Salt Lake City Health Care System, UT, USA.
Hanadi FarrukhDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA.
Arsalan N HabibDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA.
Terrence BjordahlDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA.
Debra L SimmonsDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA; Department of Veterans Affairs, Salt Lake City Health Care System, UT, USA.
Mark MungerUniversity of Utah School of Pharmacy, The University of Utah, Salt Lake City, USA.
Greg StoddardDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA.
Donald E KohanDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA; Department of Veterans Affairs, Salt Lake City Health Care System, UT, USA.
Tom GreeneDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA.
Yufeng HuangDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, USA.
University of Utah · USVA Salt Lake City Healthcare System · US

Funding

SPRINT - Factors Affecting Atherosclerosis Study (FAST)R01DK091437 · NIDDK · UNIVERSITY OF UTAH · PI BEDDHU, SRINIVASAN · 2011 to 2014
$2.3M
Adipokines in Hemodialysis PatientsR01DK078112 · NIDDK · UNIVERSITY OF UTAH · PI BEDDHU, SRINIVASAN · 2008 to 2011
$2.2M
Protein intake, nutrition and cardiovascular disease in stage V CKDR01DK077298 · NIDDK · UNIVERSITY OF UTAH · PI BEDDHU, SRINIVASAN · 2007 to 2011
$1.4M
NIDDK NIH HHS R01 DK077298NIDDK NIH HHS R01 DK078112NIDDK NIH HHS R01 DK091437
6 · The paper itself

Abstract

backgroundIn observational studies, higher uric acid levels are associated with metabolic syndrome, diabetes, and kidney disease.

objectiveThe objective of this study is to examine whether reduction of plasma uric acid with febuxostat, a xanthine oxido reductase inhibitor, impacts adipose tissue oxidative stress, adipokines, and markers of systemic inflammation or kidney fibrosis.

designThis was a double-blinded randomized controlled trial.

settingAcademic university setting was used. PATIENTS: Overweight or obese adults with hyperuricemia and type 2 diabetic nephropathy were included. MEASUREMENTS: Adipose tissue thiobarbituric acid reducing substances (TBARS) and adiponectin concentrations and urinary transforming growth factor-β (TGF-β) were primary endpoints. Plasma C-reactive protein, high molecular weight-adiponectin, interleukin-6, tumor necrosis factor-α, and TBARS and albuminuria were among predefined secondary endpoints.

methodsParticipants were randomly assigned to febuxostat (n = 40) or matching placebo (n = 40) and followed for 24 weeks.

resultsBaseline plasma uric acid levels were 426 ± 83 µmol/L; 95% completed the study. Estimated glomerular filtration rate (eGFR) declined from 54 ± 17 mL/min/1.73 m LIMITATIONS: Relatively modest sample size and short duration of follow-up.

conclusionsIn this population with progressive diabetic nephropathy, febuxostat effectively reduced plasma uric acid. However, no detectable effects were observed for the prespecified primary or secondary endpoints.

trial registrationThe study was registered in clinicaltrials.gov (NCT01350388).

Indexed as

chronic kidney disease (CKD)diabetic nephropathyfibrosisinflammationoxidative stress

Identifiers

PMID28270924
PMCPMC5332087
OpenAlexW2560479865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.